Do certain diabetes drugs increase the risk of acute kidney injury in patients taking anti-cancer therapies?

Glucagon-like peptide-1-receptor agonists (GLP-1RA) are medications that are increasingly prescribed for patients with type 2 diabetes and congestive heart failure. Reports of GLP-1RA–associated acute kidney injury (AKI) have emerged, but the risk of GLP-1RA–associated AKI among patients on anti-cancer drugs is unclear.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup